CRIS Current Research Information System

BRANDI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.171
AS - Asia 16.076
EU - Europa 10.654
Continente sconosciuto - Info sul continente non disponibili 1.025
AF - Africa 907
SA - Sud America 879
OC - Oceania 23
AN - Antartide 1
Totale 47.736
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.850
VN - Vietnam 4.469
SG - Singapore 4.462
CN - Cina 3.831
GB - Regno Unito 2.280
IT - Italia 1.837
DE - Germania 1.318
SE - Svezia 1.242
HK - Hong Kong 1.025
IN - India 729
FR - Francia 713
RU - Federazione Russa 614
BR - Brasile 603
IE - Irlanda 568
CH - Svizzera 464
UA - Ucraina 338
NL - Olanda 315
KR - Corea 304
FI - Finlandia 299
BD - Bangladesh 250
JP - Giappone 249
ZA - Sudafrica 229
CI - Costa d'Avorio 192
TG - Togo 179
CA - Canada 165
EE - Estonia 160
SC - Seychelles 148
ID - Indonesia 109
JO - Giordania 105
AR - Argentina 103
PH - Filippine 93
AT - Austria 90
BG - Bulgaria 89
TH - Thailandia 70
NG - Nigeria 66
BE - Belgio 64
IQ - Iraq 61
MX - Messico 60
PL - Polonia 53
TR - Turchia 50
GR - Grecia 40
TW - Taiwan 40
CL - Cile 39
EC - Ecuador 38
PK - Pakistan 38
ES - Italia 36
CO - Colombia 32
MY - Malesia 29
SA - Arabia Saudita 27
PY - Paraguay 24
HR - Croazia 22
IR - Iran 22
UZ - Uzbekistan 21
JM - Giamaica 20
LT - Lituania 20
RO - Romania 20
AU - Australia 19
CR - Costa Rica 19
VE - Venezuela 18
MA - Marocco 15
PS - Palestinian Territory 14
AE - Emirati Arabi Uniti 13
EG - Egitto 13
PE - Perù 13
CZ - Repubblica Ceca 11
ET - Etiopia 11
LB - Libano 11
TN - Tunisia 11
KZ - Kazakistan 10
PT - Portogallo 10
DZ - Algeria 9
GT - Guatemala 8
KE - Kenya 8
NI - Nicaragua 8
NP - Nepal 8
SV - El Salvador 8
AZ - Azerbaigian 7
DK - Danimarca 7
HN - Honduras 7
A2 - ???statistics.table.value.countryCode.A2??? 6
AL - Albania 6
GH - Ghana 6
HU - Ungheria 6
SI - Slovenia 6
PR - Porto Rico 5
UY - Uruguay 5
BB - Barbados 4
BO - Bolivia 4
IL - Israele 4
NO - Norvegia 4
OM - Oman 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
TT - Trinidad e Tobago 4
AO - Angola 3
GE - Georgia 3
LK - Sri Lanka 3
LV - Lettonia 3
MD - Moldavia 3
Totale 46.663
Salva come PNG Salva come JPEG
Città #
Singapore 3.079
Southend 1.998
Ashburn 1.657
Chandler 1.329
Fairfield 1.287
San Jose 1.217
Hong Kong 961
Ho Chi Minh City 916
Dong Ket 832
Hanoi 802
Santa Clara 775
Dallas 695
Princeton 634
Houston 608
Wilmington 600
Hefei 592
Woodbridge 579
Seattle 538
Beijing 531
Council Bluffs 521
Dublin 518
Boardman 513
Bern 438
Cambridge 425
Bologna 394
Ann Arbor 371
Lauterbourg 313
New York 299
Los Angeles 293
Helsinki 243
Seoul 234
Tokyo 215
Nanjing 210
Westminster 202
Abidjan 192
Jacksonville 192
Lomé 179
Padova 171
Berlin 152
Milan 141
Buffalo 135
Jinan 129
Da Nang 122
Redondo Beach 122
San Diego 120
Haiphong 117
Frankfurt am Main 115
Menlo Park 112
Amman 102
Medford 100
Saint Petersburg 96
Guangzhou 94
Shenyang 92
Redmond 89
Shanghai 89
Rome 87
São Paulo 87
Sofia 85
Changsha 81
Chicago 81
Turin 79
Hebei 77
Florence 68
Jakarta 68
Nanchang 63
Brussels 58
Mülheim 57
Bar Harbor 56
Bengaluru 56
London 56
Nuremberg 55
Tianjin 53
Munich 52
Toronto 52
Vienna 51
Jiaxing 50
Orem 49
Phoenix 49
Zhengzhou 46
Abeokuta 45
Hangzhou 44
San Francisco 44
Des Moines 43
Brooklyn 41
Montreal 41
Can Tho 40
Amsterdam 39
Yubileyny 39
Hải Dương 37
Redwood City 37
Biên Hòa 36
Atlanta 35
Dearborn 35
Lappeenranta 35
Olalla 34
Warsaw 34
Ninh Bình 33
Norwalk 33
Pune 33
The Dalles 33
Totale 29.787
Salva come PNG Salva come JPEG
Nome #
Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms 403
Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case–control analysis 402
Adjuvant treatment in biliary tract cancer 347
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 306
SUSTAINED COMPLETE RESPONSE OF ADVANCED HEPATOCELLULAR CARCINOMA WITH METRONOMIC CAPECITABINE: A REPORT OF THREE CASES 305
An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone 286
Genome-wide analysis identifies MEN1 and MAX mutations and a neuroendocrine-like molecular heterogeneity in Quadruple WT GIST 284
Heterotopic segmental liver transplantation on splenic vessels after splenectomy with delayed native hepatectomy after graft regeneration: A new technique to enhance liver transplantation 266
Circadian variations of rectal cell proliferation in patients affected by advanced colorectal cancer. 264
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. 264
Adjuvant chemotherapy for resected colorectal cancer metastases: literature revision and meta-analysis 262
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. 259
An atlas for clinical target volume definition, including elective nodal irradiation in definitive radiotherapy of biliary cancer 254
Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients 253
Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations 252
Antiprotease strategy in combination with gemcitabine as a putative novel therapeutic approach for pancreatic cancer treatment 251
Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study. 251
Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study 250
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 248
Antitumoral Efficacy of Two Turmeric Extracts According to Different Extraction Methods in Hepatocellular Carcinoma Cell Lines 246
Evolving knowledge in surgical oncology of pancreatic cancer: from theory to clinical practice-a fifteen-year journey at a tertiary referral centre 236
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 236
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 231
Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST) 231
Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib. 229
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 229
Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene. 228
Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer:A literature review and report of two cases 224
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 224
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study 222
Clinical Target Volume in Biliary Carcinoma: A Systematic Review of Pathological Studies. 222
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies 220
Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer 218
Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST) 217
Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis 217
Asbestos: a putative risk factor for intrahepatic cholangiocarcinoma 216
Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention 216
Second surgery or chemotherapy for relapse after radical resection of colorectal cancer metastases. 213
Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients? 213
Changes in the surgical approach to hilar cholangiocarcinoma during an 18-year period in a Western single center 212
An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor 212
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 211
Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression 211
Venous thromboembolism and port-related thrombosis in metastatic colorectal cancer patients: a monocenter experience. 210
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 210
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 210
Cell proliferation and ultrastructural changes of the duodenal mucosa of patients affected by familial adenomatous polyposis. 207
HIV enteropathy: undescribed ultrastructural changes of duodenal mucosa and their regression after triple antiviral therapy. A case report 206
219 MiR-21 expression correlates with prognosis in extrahepatic radically resected cholangiocarcinomas treated with gemcitabine-based adjuvant chemotherapy 206
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 204
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 204
Molecular imaging and targeted therapies in oncology: new concepts in treatment response assessment. a collection of cases. 203
Bone metastases in biliary cancers: A multicenter retrospective survey 203
Complete remission of primary colon cancer in a metastatic patient treated with CPT-11 plus capecitabine. 203
Risk of duodenal adenomas in familial adenomatous polyposis to progress toward advanced neoplastic disease 201
Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: A case report. 200
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 199
In Reply 196
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma 195
Chemoradiation of locally advanced biliary cancer: A PRISMA-compliant systematic review 191
Cholangiocarcinoma: Epidemiology and risk factors 191
Dyskerin expression in human fetal, adult and neoplastic intrahepatic bile ducts: Correlations with cholangiocarcinoma aggressiveness 190
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. 190
The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation 188
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 188
ACTIVATED NF-KB IN COLORECTAL CANCER: PREDICTIVE OR PROGNOSTIC FACTOR? 186
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial 186
Treatment of colorectal cancer liver metastases 185
Searching for novel multimodal treatments in oligometastatic pancreatic cancer 183
Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases. 182
Second-line chemotherapy in patients with biliary tract cancer. 182
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies 182
The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma 181
Urease-Positive Bacteria Other than Helicobacter pylori in Human Gastric Juice and Mucosa 180
Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice 180
A multicenter survey on second-line chemotherapy for advanced biliary tract cancer 180
Postsorafenib systemic treatments for hepatocellular carcinoma: Questions and opportunities after the regorafenib trial 180
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements 179
Classic versus innovative strategies for immuno-therapy in pancreatic cancer 177
Breast carcinoma presenting as linitis plastica 177
Capecitabine(CAP) based regimens vs infusional 5FU/AF in metastatic colorectal cancer cost/effectivness: the differences across the atlantic ocean 177
Occupational exposure to asbestos and risk of cholangiocarcinoma: a population-based case-control study in four Nordic countries 177
Decreasing Albumin mRNA Expression in Cholangiocarcinomas along the Bile Duct Tree. 174
Interactions between commensal bacteria and gut sensorimotor function in health and disease. 174
Cholangiocarcinoma: From risk to prevention? 174
Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients. 173
Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival. 173
Plasma membrane localization of human equilibrative nucleoside transporter 1 (hENT-1) to predict better outcome of adjuvant gemcitabine in cholangiocarcinoma (CC) patients. 173
BIFIDOBACTERIACEAE IN THE ACHLORIDRIC STOMACH 172
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 171
Mutational Landscape of Cholangiocarcinoma According to Different Etiologies: A Review 170
Metronomic capecitabine in advanced hepatocellular carcinoma patients:a phase II study. 169
Efficacy of weekly docetaxel in locally advanced cardiac angiosarcoma 169
Intestinal Microbiota Increases Cell Proliferation of Colonic Mucosa in Human-Flora-Associated (HFA) Mice 168
EXPOSURE TO ASBESTOS: A PUTATIVE UNKNOWN RISK FACTOR FOR INTRAHEPATIC CHOLANGIOCARCINOMA 168
Chemotherapy in Patients with Advanced Cholangiocarcinoma 168
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. 168
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: An analysis of the phase 3 REACH study 168
The Protease Inhibitor Gabexate Mesylate Reduces Invasiveness and Angiogenesis in Pancreatic Cancer Cell Lines, Enhancing Gemcitabine Action 168
Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link 167
Totale 21.277
Salva come PNG Salva come JPEG
Categoria #
all - tutte 141.549
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 141.549
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.642 0 190 243 327 379 227 167 286 483 313 1.168 859
2022/20236.072 659 808 312 673 401 445 192 349 979 214 423 617
2023/20241.591 194 268 113 136 113 331 73 83 51 103 58 68
2024/20256.410 253 1.041 643 502 1.034 304 444 173 104 424 280 1.208
2025/202617.161 1.542 1.476 1.892 1.169 1.655 886 1.786 785 3.275 1.382 685 628
2026/20271.070 478 592 0 0 0 0 0 0 0 0 0 0
Totale 47.736